Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rejection Acute Renal Clear all
Completed Phase 2 Interventional Results available

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

NCT00658359
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
37
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

NCT00817206
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Jul 22, 2026, 10:00 AM EDT
Completed No phase listed Observational

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

NCT03317925
View directory record Official record
Conditions
Renal Transplant, Renin-Angiotensin System, Rejection Acute Renal, Rejection Chronic Renal, Rejection of Renal Transplant
Interventions
Renal Transplantation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
1 Year to 20 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

NCT00483756
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
37
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 22, 2026, 10:00 AM EDT
Not yet recruiting No phase listed Observational

Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes

NCT06438107
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

NCT00089947
View directory record Official record
Conditions
Renal Transplantation, Graft Rejection
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

NCT01644903
View directory record Official record
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Not applicable Interventional

Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation

NCT00579592
View directory record Official record
Conditions
Acute Rejection, Renal Transplantation
Interventions
Campath-1H, rituximab, myfortic
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 4 Interventional Results available

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

NCT00118742
View directory record Official record
Conditions
Liver Transplantation
Interventions
mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 4 Interventional

A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

NCT00363116
View directory record Official record
Conditions
Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Interventions
Daclizumab
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
23
States / cities
Davis, California • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 4 Interventional

Reference Group Trial for The ONE Study

NCT01656135
View directory record Official record
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 1 Interventional

Contrast-Enhanced Ultrasound for Kidney Transplant

NCT02911714
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Lumason Contrast-Enhanced Ultrasound
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

NCT04046549
View directory record Official record
Conditions
Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
Interventions
Belatacept, VIB4920, Thymoglobulin, Methylprednisolone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient

NCT00263328
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 4 Interventional

The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

NCT01424345
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Not listed No phase listed Observational

Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation

NCT02424227
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated No phase listed Observational

TruGraf® Testing in High-Risk Kidney Transplant Recipients

NCT04266613
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
TruGraf® Testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 22, 2026, 10:00 AM EDT
Completed No phase listed Observational

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT07415876
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Retrospective Cohort Enrollment, Prospective Cohort Enrollment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 10:00 AM EDT
Active, not recruiting No phase listed Observational

Blood Biomarkers in Pediatric Kidney Transplant Recipients

NCT05477082
View directory record Official record
Conditions
Rejection of Kidney Allograft
Interventions
Observational group
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients

NCT00975000
View directory record Official record
Conditions
Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant

NCT01106027
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

NCT03380936
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 79 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jul 22, 2026, 10:00 AM EDT